Group 1 - Sanofi Pharmaceutical (01530) saw a morning increase of over 7%, and as of the report, it rose by 5.25% to HKD 30.88, with a trading volume of HKD 401 million [1] - According to the Hong Kong Stock Exchange on November 20, Mandi International has submitted an application for a mainboard listing. The prospectus indicates that Mandi International is a leading professional consumer pharmaceutical company in China, focused on developing and providing comprehensive and long-term solutions for skin health and weight management [1] - Sanofi Pharmaceutical announced its plan to spin off its subsidiary Mandi International for independent listing on the Hong Kong Stock Exchange. After the spin-off, Sanofi will not retain any equity in Mandi International, which will operate independently [1]
三生制药早盘涨超7% 三生制药拟分拆子公司蔓迪国际独立上市